• Alias: AG-013736
    • Selective second-generation, orally bioavailable inhibitor of VEGFRs (VEGFR-1, VEGFR-2, and VEGFR-3), as well as platelet-derived growth factor receptor (PDGFR), and KIT
    • FDA approved for renal cell carcinoma
    • Recommended dose: 5 mg twice daily. May be taken regardless of food. No grapefruit or grapefruit juice
    • Half-life: 2 to 6 hours
    • Metabolism: CYP3A4 substrate
    • Common side effects: Diarrhea, hypertension, fatigue, decreased appetite, nausea/vomiting
    • Clinical pearls: Dysphonia (hoarseness) may occur while taking. Advise patients to avoid irritants and to drink plenty of fluids.
    Other topics in Targeted and Immunotherapy Agents